Binder William J, Brin Mitchell F, Blitzer Andrew, Pogoda Janice M
Dis Mon. 2002 May;48(5):323-35. doi: 10.1053/mda.2002.24423.
An open-label study and 2 double-blind, placebo-controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A. Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking action on the parasympathetic nervous system. Additional studies that control factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol.
一项开放标签研究以及两项双盲、安慰剂对照研究提供了支持证据，证明A型肉毒毒素（BTX-A）是一种治疗偏头痛的有效且耐受性良好的疗法。观察到的获益持续时间与BTX-A的已知特性一致。研究结果表明，反应可能因注射前头痛的特征（如偏头痛频率）而有所不同。据推测，BTX-A提供疼痛缓解的确切机制不仅与乙酰胆碱抑制有关，还与对副交感神经系统的阻断作用有关。控制可能与反应相关因素的其他研究可能会有助于更好地理解BTX-A对偏头痛的作用以及优化治疗方案。
